Helen Hunt Was Hospitalized After A Car Accident That Looked Absolutely Terrifying

Helen Hunt was hospitalized after a car crash in Los Angeles. She was reportedly in the backseat when another car hit her vehicle. Video of the vehicle shows it flipping over in an intersection. It’s been a scary few weeks for celebrities and car crashes. Last month, Kevin Hart was involved in a scary car crash that left him with […]

Read more

CAR T cell therapy: On the cusp of ‘an immunotherapy revolution’?

A deeper understanding of the immune system’s role in controlling cancer has helped drive “an immunotherapy revolution,” offering hope for many patients with previously incurable cancers, including children, doctors have concluded in a new report. The assessment, from two Stanford University doctors, is part of their broader analysis on lessons learned from “the first leg of the CAR T cell […]

Read more

Reducing B cells with CAR T cells is effective treatment of experimental lupus

Depleting the number of harmful B cells with a novel immunotherapy that employs modified T cells may offer an effective strategy to treat lupus, according to a new study funded by the Lupus Research Alliance. These findings offer a renewed optimism for the elimination of B cells to provide a therapeutic option in lupus and pave the way for clinical […]

Read more

Longueuil families left homeless by apartment fire find outpouring of support

In Longueuil, a string of cars double parked in front of a non-profit organization as people dropped off bags full of donations at Carrefour Mousseau on Monday. Alain Dumaresq, president of Carrefour Mousseau, says people have been dropping off donations since Sunday after kitchen fire completely destroyed a Longueuil apartment complex. The blaze killed three people and left dozens homeless. […]

Read more

New two-year data show 39 percent of NHL patients treated with CAR T remain in remission

A new article published today in The Lancet Oncology shows 39 percent of large B cell lymphoma patients treated with the chimeric antigen receptor T-cell therapy (CAR T) Yescarta (axicabtagene ciloleucel) remained in remission more than two years (27.1 months median follow up) following therapy, and more than half of the patients treated remain alive. The new long-term safety and […]

Read more